MicroRNA 375 (MIR375) is significantly down regulated in human colorectal cancer (CRC) tissues; we have previously identified MIR375 as a colon cancer associated microRNA (miRNA). We identified putative MIR375 target genes by comparing the mRNA microarray analysis data of MIR375-overexpressing cells with the candidate MIR375 target genes predicted by public bioinformatic tools. We investigated that the connective tissue growth factor (CTGF) is a direct target gene of MIR375. Expression of CTGF, a ligand of epidermal growth factor receptor (EGFR), was markedly enhanced in human CRC tissues in comparison with the corresponding normal colon tissues. We demonstrated that the expression levels of molecules in EGFR signaling pathways were regulated by MIR375 in colorectal cells. Using immunohistochemistry and the xenograft of MIR375-overexpressing colorectal cells in mice, we showed that MIR375 regulates cell growth and proliferation, angiogenesis, cell migration, cell cycle arrest, apoptosis, and necrosis in colon cells. Furthermore, results of MIR375 overexpression and cetuximab treatment indicated that the apoptosis and necrosis in colon cells were synergistically enhanced. Our results suggest that the down-regulation of MIR375 modulates EGFR signaling pathways in human colorectal cells and tissues by increasing CTGF expression; therefore, MIR375 may have a therapeutic value in relation to human CRC.
Colorectal cancer (CRC) is a common malignant tumor and is the third leading cause of cancer-related mortality worldwide. 1, 2 Overall survivals of patients with advanced CRC have not improved much in spite of significant advances in the management of CRC. Therefore, there is a need for further exploration of the molecular mechanisms underlying CRC tumorigenesis and for identification of the genes that are crucial for this deadly cancer. MicroRNAs (miRNAs) are endogenously expressed small noncoding RNAs that bind to the 3 0 untranslated region (3 0 UTR) of their target mRNAs, leading to mRNA degradation or inhibiting translation. 3 Accumulating evidence suggests that miRNAs act as tumor suppressors or oncogenes by targeting genes involved in cell proliferation, survival, apoptosis and metastasis. [4] [5] [6] Actually, miRNAs have been shown to play important roles in many types of cancer. MIR375 is encoded by the chromosomal region 2q35 in humans. MIR375 has dual functions as a tumor suppressor 8, 9 and an oncogene. 10, 11 These dual functions of MIR375 depend on the targets. Recent expression profiling studies have shown that the expression of MIR375 is significantly reduced in various types of cancer including CRC. 12 In our previous study, MIR375 was identified both as a CRC 13 and a dextran sulfate sodium (DSS)-induced mice colitis 14 associated miRNA by miRNA expression profiling of CRC tissues versus healthy colorectal tissues and DSS-induced colitis versus healthy colons, respectively. MIR375 was found to be significantly downregulated in both CRC and DSS-induced colitis tissues.
The connective tissue growth factor (CTGF, also known as CCN2, NOV2, HCS24 or IGFBP8) was discovered during the screening of a cDNA expression library from human vein endothelial cells. 15 CTGF is considered a multifunctional signaling modulator involved in a wide variety of biological and pathological processes, including cell proliferation, adhesion, migration, and extracellular-matrix synthesis and has also been identified as a promitogenic and proangiogenic cofactor. [16] [17] [18] [19] [20] CTGF is a predominant regulator activated during CRC tumorigenesis and metastasis. 21 In this study, we identified the target genes of MIR375, and analyzed their function in colon cancer cells or human colorectal tissues. We identified CTGF as a MIR375 target gene in CRC and analyzed its functions in colon cancer cell lines. Overall, we demonstrated that MIR375 regulates cell proliferation and migration in colon cancer cells by suppressing the CTGF-epidermal growth factor receptor (EGFR) signaling pathway.
Material and Methods

Patients and tissue samples
The tissue samples used in this study were provided by the Biobank of Wonkwang University Hospital, a member of the National Biobank of Korea. With approval from the institutional review board and informed consent (WKIRB-201310-BR-00 l), we obtained colon cancer tissue samples from 11 patients with colon cancer (7 males and 4 females) and rectal cancer tissue samples from 2 patients with rectal cancer (2 males). The mean ages of the colon cancer patients and rectal cancer patients were 65.6 and 72 years, respectively. Four colon cancer tissue samples and matching healthy colon tissue samples (2 males and 2 females) were used to validate the endogenous MIR375 expression level. In addition, 1 separate colon cancer tissue sample with a matching healthy colon tissue sample and 2 rectal cancer tissue samples with matching healthy rectal tissue samples were used to assess CTGF mRNA expression. Six separate colon cancer tissue samples and matching healthy colon tissue samples (4 males and 2 females) were used to analyze CTGF protein expression levels.
Cells culture and reagents
The human CRC cell lines Caco2, SW480, HT29 and HCT116 were obtained from Korea Cell Line Bank (KCLB, Seoul, Korea) or American Type Culture Collection (ATCC, Manassas, VA). SW480, HCT116 and HT29 cells were cultured in RPMI 1640 (HyClone, Logan, UT) supplemented with 10% FBS in a humidified atmosphere containing 5% of CO 2 at 378C. Caco2 cells were cultured in a-MEM (HyClone) supplemented with 20% FBS in a humidified atmosphere containing 5% of CO 2 at 378C.
RNA extraction and quantitative real-time PCR
Total RNA was isolated with the TRIzol reagent (Invitrogen, Carlsbad, CA). After digestion with DNase and cleanup, RNA samples were quantified, aliquoted, and stored at 2808C. Total RNA samples that were isolated from the tissue samples and/or cultured cells were used as a template to synthesize cDNA for quantitative real-time polymerase chain reaction (qRT-PCR) by means of a StepOne Real-time PCR system (Applied Biosystems, Foster City, CA).
The differential miRNA expression patterns were validated by the TaqMan qRT-PCR assay (Applied Biosystems) or the NCode VILO miRNA cDNA Synthesis kit for qRT-PCR and Express SYBR GreenER miRNA qRT-PCR kit (Invitrogen). qRT-PCR with the SYBR Green dye (Applied Biosystems) was used to assess mRNA expression. RNU48 (for TaqMan qRT-PCR) or 5.8S (for SYBR qRT-PCR) and GAPDH served as endogenous controls for qRT-PCR of miRNA and mRNA, respectively. Each sample was analyzed by qRT-PCR in triplicate. Primers for both qRT-PCR and TaqMan analysis are listed in Supporting Information Table S1 .
Transfection of oligonucleotides
Molecules that mimic endogenous MIR375 (hsa-miR-375, Pre-miRNA precursor AM17100), anti-MIR375 (Anti-hsamiR-375, Pre-miRNA precursor AM17000), and negative control were synthesized commercially (Ambion, Austin, TX) and transfected at 50 nM. Transfection of oligonucleotides was carried out according to our previously described methods. 13, 14 Negative control small interfering RNA (siRNA;
Ambion, Austin, TX) and CTGF siRNA (Santa Cruz Biotechnology, Santa Cruz, CA) were transfected according the instructions of the supplier.
mRNA expression profiling to find MIR375 target genes SW480 and Caco2 cells were transfected with MIR375 or MIR1 as a control. Total RNA was isolated 48 hr after the
What's new?
In the search for a deeper understanding of molecular mechanisms underlying tumorigenesis in colorectal cancer (CRC), microRNAs have emerged as intriguing players. In particular, miR375, which is significantly downregulated in CRC, is of interest for its potential involvement in CRC suppression. This study suggests that connective tissue growth factor (CTGF), a signaling modulator activated in CRC tumorigenesis, is a direct target gene of miR375. In CRC cells, miR375 overexpression was found to downregulate EGFR signaling pathways via direct CTGF downregulation. Both in vitro and in vivo, miR375 overexpression regulated cell proliferation, angiogenesis, and cell death, functions relevant to tumor suppression.
transfection, amplified, and purified using the Illumina TotalPrep RNA Amplification Kit (Ambion) to obtain biotinylated complementary RNA. Hybridization of the samples, signal detection, array scanning, data analysis, and filtering were carried out by our previously described methods.
13,14
A luciferase reporter assay
Wild-type or mutant fragments of the 3 0 UTR of CTGF containing the predicted binding site for MIR375 were amplified by PCR using the primer set shown in Supporting Information Table S1 . Analysis of the results of the luciferase assays was carried out according to our previously described method. 13, 14 Bioinformatic analysis of miRNA
The TargetScan (http://www.targetscan.org) and miRWalk (http://www.umm.uni-heidelberg. de/apps/zmf/mirwalk/index. html) algorithms were used to identify putative targets of MIR375.
Protein extraction and western blot analysis
Membranes with proteins were then incubated overnight at 48C with primary antibodies to EGFR, p-AKT1, KRAS and p-ERK1/2, IGF1R and YAP1 (Cell Signaling Technology, Carlsbad, CA), CTGF, AKT, ERK1/2, PIK3CA, BRAF, TGFB1 and PKCA (Santa Cruz Biotechnology, Santa Cruz, CA). Protein extraction and western blot analysis were carried out according to our previously described methods.
13,14
The cell viability assay and migration assay
The cell viability assay and migration assay were carried out according to our previously described methods. 13, 14 Flow cytometric analysis After transfection with MIR375 or siCTGF or control in 6-well plates for 72 hr, we analyzed the cell cycle in HCT116 and HT29 cells (10 5 /well) by flow cytometry as follows. Five hundred microliters of trypsin was added for detachment of the cells, which were washed twice with PBS before the cell pellets were resuspended in PBS and fixed in 70% ice-cold ethanol (v/v) overnight at 2208C. The fixed cells were incubated in PBS containing 50 mg/mL RNase A, 0.25% Triton X-100 and 0.1 mM EDTA for 30 min at 378C. Propidium iodide (PI) was added to the cell suspension at the final concentration of 100 lg/mL, and the mixture was incubated for 15 min while covered with aluminum foil at room temperature. The cell cycle was analyzed by flow cytometry using the Cell Quest software and a FACSCalibur instrument (Becton Dickinson). Apoptosis and necrosis were analyzed by flow cytometry with the Annexin V-fluorescein isothiocyanate Apoptosis Detection Kit according to our previously described method, 13 using the HCT116 or HT29 cells transfected with MIR375, siCTGF, or control mock. Cetuximab (Erbitux; Merck, Darmstadt, Germany) was diluted with the medium to obtain the required final concentration before each experiment. Cetuximab (70 mg/mL) was added 24 hr after the transfection of MIR375 (50 nM), and the HCT116 or Caco2 cells were then incubated for 48 hr.
Transwell migration assays
The Cytoselect 24-well Cell Migration Assay Kit (8 lm, CBA100, Cell Biolabs, San Diego, CA) was used to assess migration of the cells. The cells suspension was placed into the top chamber of each insert. The Transwell chambers with upper and lower culture compartments were separated by polycarbonate membranes with 8-lm pores. Five hundred microliters of the RPMI 1640 medium containing 10% FBS was added into the bottom chamber to act as a chemoattractant, and the plate was incubated for 24 hr at 378C in an incubator with a humidified atmosphere containing 5% of CO 2 . After 24 hr, the cells that did not migrate were removed from the upper side of the Transwell membrane filter inserts using a cotton-tipped swab. Migrating cells on the bottom side were stained with 400 lL of 0.1% crystal violet and washed several times in a beaker with water.
The xenograft model based on nude mice
Athymic female BALB/c nude mice (8 weeks old, 19-21 g) were purchased from Charles River Technology (Boston, MA) through Orient Bio Inc. (Sungnam, Gyeonggi, South Korea). The mock control or MIR375 or siCTGF were prepared by preincubating 100 nmol of miRNAs with 10 mL of Lipofectamine RNAiMAX (Invitrogen, Carlsbad, CA) for 15 min and by mixing with HCT116 or HT29 (10 7 cells) in a final volume of 200 mL in the RPMI 1640 medium. Then, the transfected cells were injected subcutaneously into both sides of the posterior flank of mice. Tumor progression was evaluated every 5 days by means of digital calipers and the formula for volume [(longest diameter) 3 (shortest diameter) 2 3 0.525]. On Day 20, the tumor-bearing mice were euthanized and subjected to necropsy where tumors were excised with a scalpel from the circumferential tissues and fixed in 10% neutrally buffered formalin, were embedded in paraffin, and 4-mm slices were prepared and stained with H&E. All the mice were housed and maintained under specific pathogen-free conditions in mesh cages under light illumination for 12 hr a day. All surgical and care procedures that were administered to the animals were in accordance with the Animal Care Committee of Wonkwang University (WKU14-47).
Immunohistochemistry
Immunohistochemistry assay was carried out according to our previously described methods.
14 The antibodies and dilutions were as follows: proliferating cell nuclear antigen (PCNA), a biotinylated monoclonal antibody clone PC10 
Statistical analysis
Each experiment was repeated at least 3 times, and consistent results were obtained. All of the data were expressed as mean 6 standard deviation (SD). The differences between groups were analyzed by means of the GraphPad Prism 5.0 statistical software (GraphPad Software, San Diego) or Student's t test. Differences with a p values <0.05 were regarded as statistically significant.
Results
The MIR375 expression level in colon cancer tissues
We found that MIR375 is down-regulated in human CRC tissue. To confirm this result, we compared MIR375 expression in 4 human healthy colon tissue samples and the matching colon cancer tissues by qRT-PCR. MIR375 expression levels were significantly reduced in CRC tissue (p < 0.01; Fig. 1a ).
mRNA expression profiling in MIR375-overexpressing cells
To determine the levels of endogenous MIR375 in Caco2, HCT116, HT29 and SW480 cells, we carried out qRT-PCR analysis using the total RNA isolated from the three different cell lines. As shown in Figure 1b , the MIR375 level was the highest in HT29 cells and lower in HCT116 and Caco2 cells (Fig. 1b) . Hypermethylation of MIR375 has been demonstrated in CRC cell lines including HCT116 and SW480. Down regulation of MIR375 in HCT116 and SW480 cells compared with HT29 cells is due to hypermethylation of MIR375 in HCT116 and SW480 cells. However HT29 cells have no MIR375 methylation. 22 To identify the genes downregulated by MIR375 overexpression, pre-MIR375 was transfected into Caco2 or SW480 cells. Increased expression of MIR375 was observed 24 hr after transfection of HCT116, HT29, SW480 or Caco2 cells, thus confirming the transfection efficiency (Supporting Information Fig. S1A ). The cells were harvested, and mRNAs were isolated 48 hr after the MIR375 transfection for mRNA expression profiling analysis by means of the Illumina HumanHT-12 v4 Expression BeadChip. We identified 31 genes whose expression was downregulated 1.5-fold in the cells overexpressing MIR375 (Supporting Information Table S2 ).
Identification of MIR375 target genes
For this purpose, we compared the 31 candidate target genes identified by the mRNA microarray analysis with the candidate MIR375 target genes predicted by the TargetScan and miRWalk algorithms. Of the 31 genes, 13 were finally identified as putative targets of MIR375 (Table 1) . Among them, we focused on the CTGF gene in this study. The endogenous CTGF level was almost similar among the SW480, HT29 and HCT116 cell lines (Supporting Information Fig. S1B ). Next, we tested whether MIR375 regulates CTGF mRNA and protein levels in HT29 cells. The CTGF mRNA level was lower in HT29 cells transfected with pre-MIR375 than in untransfected control cells (p < 0.01; Fig. 2a) . The cellular and extracellular (secreted into culture media) CTGF protein expression levels were also significantly reduced in MIR375-overexpressing SW480 and HT29 cells (p < 0.01; Fig. 2b ).
CTGF expression in human CRC tissues
On the basis of the findings described above, we evaluated CTGF expression in 6 human colon cancer tissues and the matching healthy colon tissues by qRT-PCR and by western blotting. CTGF mRNA expression was increased in all colon cancer tissue samples when compared to the expression in healthy colon tissues (p < 0.01, Fig. 2c ). CTGF protein expression was also increased (5 of the 6 pairs) in colon cancer tissues (Fig. 2d) .
CTGF is a direct target of MIR375
To demonstrate a direct interaction between the CTGF 3 0 UTR and MIR375, we cloned the WT CTGF 3 0 UTR region (predicted to interact with MIR375) into a luciferase reporter vector (Fig. 2e) . Luciferase activity was reduced by 28%, when the cells were co-transfected with pre-MIR375 (p < 0.01, Fig. 2f ). As a control experiment, we cloned a mutated CTGF 3 0 UTR sequence lacking 8 of the complementary bases (Fig. 2e) . As expected, repression of the luciferase activity was abrogated when the interaction between MIR375 and its target 3 0 UTR was disrupted (Fig. 2f) . As additional control experiments, MIR1 instead of MIR375 was cotransfected with the WT and mutated CTGF 3 0 UTR constructs. Transfection of pre-MIR1 did not affect the luciferase activity of either construct (Fig. 2f) .
MIR375 regulates CTGF-EGFR signaling pathways
We then determined which receptor (EGFR or IGF1R) is mainly regulated by means of MIR375-transfected or CTGF siRNA (siCTGF)-transfected colorectal cells. EGFR was more significantly affected (Fig. 3a) by MIR375 or siCTGF overexpression than IGF1R was (Supporting Information Fig. S3A ). This result led us to focus on the CTGF-EGFR signaling in colon cancer cells.
To determine the functional interaction between MIR375 and CTGF in HT29 cells (KRAS WT, and BRAF and PIK3CA mutated), SW480 cells (BRAF and PIK3CA WT and KRAS mutated) and HCT116 cells (BRAF WT, and KRAS and PIK3CA mutated; Ahmed et al., 2013), we analyzed expression of the proteins involved in the CTGF-EGFR cellular signaling by western blot analysis. EGFR, p-EGFR, PIK3CA, AKT and p-AKT protein expression levels were reduced by MIR375 transfection in HT29, SW480 and HCT116 cells, respectively (Fig. 3a) . These results indicated that MIR375 regulates the CTGF-EGFR-PIK3CA-AKT pathway in colon cancer cells. KRAS protein expression was almost unchanged by the MIR375 transfection in both HT29 and HCT116 cells, respectively (Fig. 3b) .
ERK1/2 (p < 0.01) and p-ERK1/2 (p < 0.01) protein expression was decreased significantly by MIR375 transfection of HT29 and HCT116 cells, respectively (Fig. 3b) . These results indicated that there is another signaling pathway for EGFR and ERK1/2 that does not involve KRAS.
CTGF gene silencing downregulates EGFR-AKT-p-AKT signaling
On the basis of the above results, we tested whether CTGF gene silencing by the siCTGF duplex affects the EGFR-AKT 
01). (c) Silencing of CTGF decreases EGFR, p-EGFR, AKT and p-AKT levels in HCT116 cells, (d) but not KRAS, ERK or p-ERK expression in HT29 cells.
We conducted three independent experiments, and the p values were calculated by the t test (ns: not significant, *p < 0.05; **p < 0.01). (e) The expression levels of KRAS, BRAF, ERK1/2 and p-ERK1/2 are not changed in CaCO 2 cells by CTGF silencing. We performed three independent experiments, and the p values were calculated by the t test (ns: not significant, *p < 0.05).
or EGFR-KRAS-ERK signaling pathway. Western blotting results showed that CTGF (p < 0.01), EGFR (p < 0.05 and 0.01), p-EGFR (p < 0.05 and 0.01), AKT (p < 0.05) and p-AKT (p < 0.01 and 0.05, respectively) protein expression levels were markedly down-regulated by siCTGF transfection in HCT116 and SW480 cells, respectively (Fig. 3c) . KRAS and ERK1/2 expression levels were not decreased by CTGF gene silencing in HT29 cells (Fig. 3d) . These findings suggested that CTGF regulates only the EGFR-PIK3CA-AKT signaling cascade not the EGFR-KRAS-ERK pathway.
MIR375 regulates both EGFR signaling pathways
To confirm the MIR375-or CTGF-mediated pathways in CRC, we quantified expression of relevant proteins in Caco2 cells (KRAS, BRAF and PIK3CA WT) after MIR375 or siCTGF transfection. KRAS, BRAF, ERK1/2 and pERK1/2 expression levels were not changed by siCTGF transfection in Caco2 cells (Fig. 3e) . This result clearly indicated that CTGF regulates only the EGFR-PIK3CA-AKT signaling pathway not the EGFR-KRAS-ERK signaling pathway. BRAF, ERK1/2 and p-ERK1/2 expression levels were significantly reduced by MIR375 overexpression (p < 0.05; Fig. 3e ). Although KRAS was also slightly down-regulated in Caco2 cells by MIR375 overexpression, this change was not statistically significant (p 5 ns; Fig. 3e ).
MIR375 inhibits CRC cell viability and cell cycle progression
We explored the biological functions of MIR375 in CRC cells. MTT assays showed that cell viability was stably reduced by MIR375 transfection in colon cancer cell lines SW480 (p < 0.05), HT29 (p < 0.01) and HCT116 (p < 0.05; Fig. 4a ). In addition, forced overexpression of MIR375 resulted in significant accumulation of the G 1 population among HCT116 cells (p < 0.01) and HT29 cells (p < 0.05), respectively (Fig. 4b) . This result indicated that MIR375 inhibited cell cycle progression in colon cancer cells.
Effects of MIR375 transfection on apoptosis in colon cancer cells
We evaluated apoptosis rates in MIR375 or mock-transfected colon cancer cell lines. As shown in Figure 4c and Supporting Information Figure S4A , apoptosis and necrosis in HT29 cells was stably enhanced after MIR375 transfection (Fig. 4c , p < 0.01) and siCTGF transfection (Supporting Information  Fig. S4A , p < 0.01). The stably increased apoptotic and necrotic cell numbers were also observed in MIR375-transfected HCT116 cells (Fig. 4c , p < 0.01) and siCTGFtransfected HCT116 cells (Supporting Information Fig. S4A , p < 0.01). The migratory ability of MIR375-or siCTGF-transfected colon cancer cells As shown in Figure 4d , in the scratch wound assay, the cell migratory ability was significantly inhibited in HCT116 cells transfected with MIR375 (Fig. 4d) . The cell migration ability in MIR375-transfected cells was significantly decreased 48 hr (p < 0.05) and 72 hr (p < 0.01) after the transfection (Fig.  4d) . The ability of HCT116 cells to migrate through the insert membrane was also significantly inhibited by MIR375 (Fig. 4e , upper panel, p < 0.01) or by siCTGF (Fig. 4e , lower panel, p < 0.05).
Effects of MIR375 on tumor growth in mice with a xenograft of colon cancer cells
To study the effects of MIR375 on tumor growth in vivo, we used a xenograft tumor model consisting of athymic nude mice with subcutaneously implanted HCT116 or HT29 cells. After 20 days of transfection, mean tumor volume of MIR375-transfected cells was 332.7 6 26.2 mm 3 (HCT116) and 255.45 6 15.05 mm 3 (HT29) and was significantly smaller than that in mock cells (532.9 6 25.2 and 357.9 6 20.1 mm 3 , respectively; p < 0.01; Figs. 5a and 5b). As compared to the mock control, the average tumor weight of MIR375-transfected cancer cells was significantly reduced in both cell lines: HCT116 and HT29 (Fig. 5b , p < 0.01). We also compared with the mock control, the average tumor volume of siCTGF-transfected cancer cells was significantly reduced in both cell lines: HCT116 and HT29 (Supporting Information Fig. S4B ). This result indicated that the proliferative ability was reduced by MIR375 overexpression.
Histopathology in mice with a xenograft of MIR375-transfected colon cancer cells
The tumors were analyzed histologically using H&E and immunohistochemically using antibodies against PCNA, Ki67, and CD31. PCNA-or Ki67-immunoreactive cells were found in the xenografted tumors, and the PCNA-or Ki67-positive cells were quantified by histological analysis. MIR375-transfected tumors contained significantly decreased numbers of PCNA-or Ki67-positive cells compared with mock control tumors for both HCT116 and HT29 cells (p < 0.01; Fig. 5c ).
Effects of MIR375 on tumor angiogenesis in mice with a xenograft of colon cancer cells
We checked the effect of MIR375 on angiogenesis in mice bearing HCT116 or HT29 cells xenografts. As for angiogenesis, CD31 immunohistochemical analysis revealed that the blood vessel network was well developed in the tumors from the mock control, whereas the development of the blood vessel network appeared to be inhibited by MIR375 for both HCT116-and HT29-derived tumors (p < 0.05; Fig. 5d ). These results suggested that the decreased cell density may be due to impairment of angiogenesis by MIR375. We also checked the effect of CTGF on proliferation ability and angiogenesis in mice bearing HT29 cells xenografts. siCTGF-transfected tumors contained significantly decreased numbers of Ki67-positive cells (p < 0.05) and CD31-positive blood vessel networks (p < 0.01) compared with mock control tumors for both HT29 cells (Supporting Information Fig. S4C ).
The synergistic effects of MIR375 and cetuximab on apoptosis or necrosis in colon cancer cells
We examined the IC 50 values of cetuximab using the MTT assay. The IC 50 of cetuximab for HCT116 cells was 350 6 0.02 mg/mL for 48 hr incubation. HCT116 cells were treated with 70 mg/mL cetuximab, at a 1/5 concentration of IC 50 . We tested whether MIR375 plays a functional role in cetuximab-induced apoptosis or necrosis. The apoptosis and necrosis rates were significantly increased (p < 0.05) in HCT116 cells after cetuximab treatment as compared with untreated control cells (Fig. 4f) . MIR375 overexpression increased (p < 0.05) the cetuximab-induced apoptosis and necrosis in HCT116 cells compared with the cells treated with cetuximab alone (Fig. 4f) . These results showed that overexpression of MIR375 upregulated the cetuximabinduced apoptosis and necrosis in colon cancer cells (Fig. 4f ).
Discussion
In this study, we showed that MIR375 expression was downregulated in human colon cancer tissues compared with matching healthy colon tissues (Fig. 1a) . In addition to our results, down-regulation of MIR375 has been demonstrated in several types of cancer, such as HCC, gastric cancer, melanoma and glioma. [23] [24] [25] [26] MIR375 is up-regulated in other tumors such as prostate cancer 11 and breast cancer. 27 In our previous study, MIR375 was identified both as a CRC 13 and a DSS-induced mice colitis 14 associated miRNA by miRNA expression profiling of CRC tissues versus healthy colorectal tissues and DSSinduced colitis versus healthy colons, respectively. In present study, we found that MIR375 regulates CTGF and the CTGF-EGFR signaling pathway by directly down-regulating CTGF expression in colorectal cells (Figs. 2 and 3 ). These data suggest that the CTGF-EGFR signaling cascade is up-regulated in CRC as a result of reduced MIR375 expression. The p values were calculated by the t test (*p < 0.05). (e) The EGFR signaling is regulated by MIR375 in human colon cancer cells. The diminished MIR375 expression leads to YAP1 up-regulation and resulted in increased transcription for CTGF mRNA, and gave rise to the increasing translation of CTGF in the cytoplasm and extracellular regions. Up-regulated CTGF binds to the extracellular domain of EGFR. Activated EGFR leads to activation of the oncogene PIK3CA, which is also directly down-regulated by MIR375. Activated PIK3CA activates AKT and several downstream effectors. However, EGFR activates the oncogene KRAS, which in turn activates the oncogene BRAF, then MEK and ERK1/2, and leads to expression of growth-promoting genes in the nucleus. While CTGF regulates only the EGFR-PIK3CA-AKT signaling pathway, MIR375 regulates both EGFR-PIK3CA-AKT and EGFR-KRAS (or IGF1R-PKC)-BRAF-MEK-ERK signal pathways in colon cancer cells. Consequentially, the diminished MIR375 expression in colon cancer leads to cell survival, proliferation, migration, and angiogenesis. Solid lines and square dotted lines indicate MIR375-mediated signaling and CTGF-dependent signaling, respectively.
In CRC, high expression of CTGF correlates with an advanced clinical stage and lymph node metastasis. 28 Another study also showed that CTGF mRNA is up-regulated in CRC compared to healthy colon tissues but is down-regulated in Dukes stage C colon cancer in comparison with Dukes stages A and B. 29 Other researchers demonstrated that TAZ-AXL-CTGF co-overexpression is associated with increased expression of genes that are related to colon cancer progression. 30 We showed here that CTGF mRNA and protein are overexpressed in CRC tissues compared to adjacent non-tumorous tissues (Figs. 2c and  2d) , and that MIR375 directly reduces the expression of CTGF in colon cancer cells (Figs. 2e and 2f) . These results suggest that MIR375 targets CTGF as a potential tumor suppressor in CRC.
EGFR is phosphorylated by the binding of CTGF and activates the downstream signaling cascades. 31 The EGFR pathway is involved in several cellular responses, such as cell proliferation, migration, and differentiation. [32] [33] [34] We analyzed the CTGF-EGFR signaling cascades mediated by MIR375 in several colon cancer cells that have the most common mutations such as those in genes KRAS, PIK3CA, BRAF and TP53. 35 CTGF-EGFR signals are affected by MIR375 overexpression or by CTGF gene silencing by means of siCTGF (Fig. 3) . EGFR-PIK3CA-AKT signaling is downregulated by MIR375 overexpression in HT29, SW480 and 
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HCT116 cells (Fig. 3a) and by siCTGF in HCT116 and SW480 cells (Fig. 3c ). ERK1/2 and p-ERK1/2 expression levels are also down-regulated by MIR375 overexpression in HT29 and HCT116 cells (Fig. 3b) . Nevertheless, ERK1/2 and p-ERK1/2 expression levels are not changed by siCTGF in HT29 and Caco2 cells (Figs. 3d and 3e) . These results indicate that MIR375 regulates both the EGFR-PIK3CA-AKT pathway and EGFR-BRAF-ERK1/2 pathway, but CTGF that is affected by MIR375 is involved only in the EGFR-PIK3CA-AKT signaling pathway in colon cancer cells. These results led us to study the biological function of MIR375 in colon cancer cells, and we found that MIR375 can regulate cell proliferation (Fig. 4a) , cell cycle progression (Fig. 4b) , apoptosis and necrosis (Fig. 4c ) and cell migration (Figs. 4d and 4e) via control over EGFR signaling pathways in colon cancer cells. KRAS expression was not changed by MIR375 overexpression in HT29 and HCT116 cells (Fig. 3b) . This finding prompted us to do an additional experiment involving Caco2 cells. BRAF and p-ERK1/2 expression levels were found to be significantly reduced by MIR375 overexpression (Fig. 3e) . KRAS expression was also slightly decreased by MIR375 overexpression, without statistical significance (Fig.  3e) .
We also tested whether MIR375 directly regulates ERK expression. This is because ERK has a putative binding site for MIR375. Luciferase activity was not different between WT and mutated sequences of ERK 3 0 UTR (Supporting Information Fig. S2 ). These results suggest that MIR375 does not interact directly with ERK in colon cancer cells, and that unknown signals such as insulin-like growth factor 1 receptor (IGF1R) may exist in CRC that are controlled by MIR375. Actually, IGF1R is down-regulated by MIR375 overexpression in colon cancer cells (Supporting Information Fig. S3A ). Cells with an altered IGF1R pathway seem to escape EGFR inhibitor (cetuximab)-mediated cell death by activation of the PIK3CA pathway. 36 YAP1, TGFb1 and PKC expression levels are also down-regulated by MIR375 overexpression in colon cancer cells (Supporting Information Fig. S3B ). PIK3CA and YAP1 are 2 other target genes in colon cancer cells that have been identified as a direct target of MIR375. 22, 37 PIK3CA is a key molecule in AKT signaling, a well-recognized pathway that regulates cancer cell survival and proliferation. 33 YAP1 is mainly known as an effector of the Hippo signaling pathway involved in cell growth, division and apoptosis. 38, 39 Overexpression of MIR375 revealed significant inhibition of cell proliferation in the MTT assay (Fig. 4a) . In nude mice, colon cancer cells overexpressing MIR375 showed a significantly lower growth rate as compared with control cancer cells (Fig. 5) . The volumes, weight and cellular proliferation of a tumor xenograft of HCT116 cells or HT29 cells were significantly reduced by MIR375 overexpression (Figs.  5a-5c ). Angiogenesis was also significantly reduced in xenografts of HCT116 cells and HT29 cells by MIR375 overexpression (Fig. 5d) . In addition, flow cytometric analysis revealed significant enhancement of apoptosis in MIR375-transfected cells compared to the control cells (Fig. 4c) . Moreover, overexpression of MIR375 arrested the cell cycle in the G1 phase (Fig. 4b) . Collectively, our results indicate that MIR375 targets CTGF and functions as a tumor suppressor in colon cancer.
Cetuximab, a chimeric monoclonal antibody, is an EGFR inhibitor used for the treatment of metastatic CRC. As shown in Figure 4c , MIR375 overexpression increased the apoptotic and necrotic cell ratio among HCT116 cells. Therefore, our results suggest that MIR375 could be used to develop an anticancer therapy for human CRC. We also observed synergistic effects of MIR375 and cetuximab in HCT116 cells (Fig. 4f) . These findings indicated that combined treatment with cetuximab and MIR375 may be effective against CRC.
In summary, we showed that MIR375 expression is suppressed in the tissues of CRC patients. We identified CTGF as a putative MIR375 target gene using mRNA microarray analysis and bioinformatic tools and showed that CTGF is a direct target of MIR375. CTGF expression is increased in the tumor tissues of CRC. Our results suggest that MIR375 regulates both EGFR signaling pathways (CTGF-EGFR-PIK3CA-AKT and EGFR-KRAS-BRAF-ERK1/2) with or without CTGF-mediated expression, and as a result, MIR375 regulates cell growth and proliferation, migration, cell cycle arrest in the G 1 phase, apoptosis and/or necrosis and angiogenesis via the EGFR pathway in colon cancer cells (Fig. 5e) . We also showed that MIR375 has a synergistic anticancer effect with cetuximab on colon cancer cells.
